Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination,

Chad E Groer1, Cullen L Schmid, Alex M Jaeger

  • 1Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA.

Insights

Morphine and DAMGO differentially engage β-arrestin1 and β-arrestin2 proteins to regulate μ-opioid receptor (MOR) function, impacting internalization and ubiquitination differently.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cell Biology

Background:

  • Opioid drugs, like morphine, exert effects via the μ-opioid receptor (MOR).
  • MOR regulation involves phosphorylation, β-arrestin recruitment, and internalization, processes influenced by specific ligands.
  • Two β-arrestin forms exist (β-arrestin1 and β-arrestin2), with β-arrestin2 being the primary focus of previous research.

Purpose of the Study:

  • To investigate the distinct roles of β-arrestin1 and β-arrestin2 in regulating MOR activity.
  • To compare how different MOR agonists (morphine and DAMGO) interact with β-arrestins.

Main Methods:

  • Utilized cells lacking individual or both β-arrestin proteins.
  • Compared MOR agonist-induced β-arrestin recruitment, receptor internalization, and ubiquitination.

Main Results:

  • Morphine selectively recruits β-arrestin2, while DAMGO recruits both β-arrestin1 and β-arrestin2.
  • Both β-arrestins are necessary for MOR internalization, but only β-arrestin2 rescues morphine-induced internalization.
  • β-arrestin1 is crucial for DAMGO-induced MOR ubiquitination and dephosphorylation, potentially influencing receptor resensitization.

Conclusions:

  • Differential β-arrestin engagement dictates MOR regulatory pathways.
  • β-arrestin1 plays a key role in MOR ubiquitination and dephosphorylation, suggesting a role in opioid tolerance development.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...